Platelet Activating Factor, a Potent Mediator of Allergy, as a Structural Component of Phosphatidylcholine Vesicles

  • E. Skrika
  • C. Vakirtzi-Lemonias
Part of the NATO ASI Series book series (NSSA, volume 155)


Platelet Activating Factor, PAF, is an ether phospholipid with the structure of l–0-alkyl–2-acetyl-sn-glyceryl-3-phosphocholine, AGEPC (Demopoulos et al, 1979, Hanahan and Weintraub, 1985). It has a wide spectrum of biological activities, and in structure-function studies, it has been established that the ether bond, the length of the alkyl chain, the phosphocholine moiety, and, especially, the presence of the acetyl group at position 2 of the glycerol backbone are indispensable for the biological activity of the molecule (Pinckard et al, 1982ab, Lee and Snyder, 1986). The requirement for such a specific structure for activity is reflected to the presence of specific receptors on the surface of various cells. Thus, receptors have been established on neutrophils, platelets, and on heart, trachea and lung smooth muscles, liver, etc. (Lee and Snyder, 1986, Tuffin et al, 1985, Inarrea et al, 1984, Hwang et al, 1983).


Platelet Activate Factor Elution Profile Elution Volume Small Unilamellar Vesicle Ether Phospholipid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ashbrook, J. D., Spector, A. A., Santos, E. C., and Fletcher, J. E., 1975, Long chain fatty acid binding to human plasma albumin, B.Biol.Chem., 250, 6:2333.Google Scholar
  2. Barlow, W. M., and Klopfenstein, W. E., 1980, Effects of constituent fatty acids on the binding of lysophosphatidylcholines by serum albumin, Biochim.Biophys.Acta, 620:18.PubMedGoogle Scholar
  3. Barrow, D. A., and Lentz, B. R., 1980, Large vesicle contamination in small, unilamellar vesicles, Biochim.Biophys.Acta, 592:92.Google Scholar
  4. Bartlett, G. R., 1959, Phosphorus assay in column chromatography, J.Biol.Chem., 234:466.PubMedGoogle Scholar
  5. Benveniste, J., Henson, P. M., and Cochrane, G. G., 1972, Leucocyte-dependent histamine release from rabbit platelets. The role of I g E, basophils, and a platelet-activating factor, J.Exp.Med. 136:1356.PubMedCrossRefGoogle Scholar
  6. Berdel, W. E., Andreesen, R., and Munder, P. G., 1986a, Synthetic Alkylphospholipid analogs: a new class of antitumor agents, in: “Phospholipids and cellular regulation”, J. G. Kuo, ed., Vol. 2, CRC Press Inc., Boca Raton, Florida.Google Scholar
  7. Berdel, W. E., Von Hoff, D. D., Unger, C., Schick, H. D., Fink, U., Reichert, A., Eibl, H., and Rastetter, J., 1986b, Ether lipid derivatives: Antineoplastic activity, in vivo and the structure activity relationships, Lipids, 21:301.PubMedCrossRefGoogle Scholar
  8. Cerrina, J., Raffestin, B., Labat, C., Boullet, C., Bayol, A., Gateau, O., and Brink, C., 1983, Effects of PAF-acether on isolated muscle preparations from the rat, guinea pig and human lung, in: “Platelet activating factor and structurally related either lipids,” J. Benveniste and B. Arnoux, eds., Inserm Symposium No 23, Elsevier Science Publishers.Google Scholar
  9. Chong, C. S., and Colbow, K., 1976, Light scattering and turbidity measurements on lipid vesicles, Biochim Biophys.Acta., 436:260.PubMedCrossRefGoogle Scholar
  10. Demopoulos, C. A., Pinckard, R. N., and Hanahan, D. J., 1979, Platelet-activating factor. Evidence for I-O-alkyl-cetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid mediators), J.Biol.Chem., 254:9355.PubMedGoogle Scholar
  11. Farr, R. S., Wardlow, M. L., Cox, C. P., Meng, K. G., and Greene, O. E., 1983, Human serum acid-labile factor in an acylhydrolase that inactivates platelet-activating factor, Fed.Proc. 42:3120.PubMedGoogle Scholar
  12. Grandel, K. G., Farr, R. S., Wanderer, A. A., Eisenstadt, T. C., and Wassermann, S. I., 1985, Association of platelet activating factor with primary acquired cold urticaria, New Engl.J.Med., 313:405.PubMedCrossRefGoogle Scholar
  13. Gregoriadis, G., and Senior, J., 1980, The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation, FEBS Lett., 119:43.PubMedCrossRefGoogle Scholar
  14. Hanahan, D. J., and Weintraub, S., 1985, Platelet activating factor, Isolation, identification and assay, Methods Biochem.Anal., 31:195.PubMedCrossRefGoogle Scholar
  15. Hwang, S. B., Lee, C., Cheah, M. J., and Shen, T. Y., 1983, Specific receptor sites for l-0-alkyl-2–0-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes, Biochemistry, 22:4756.PubMedCrossRefGoogle Scholar
  16. Inarrea, P., Gomez-Cambronero, J., Nieto, M., and Sauchez-Crespo, M., 1984, Characteristics of the binding of platelet activating factor to platelets of different animal species, Eur.J.Pharmacol., 105:309.PubMedCrossRefGoogle Scholar
  17. Israelachvili, J. N., Mitchell, D. J., and Nihham, B. W., 1977, Theory of self-assembly of lipid bilayer and vesicles, Biochim.Biophys.Acta., 470:185.PubMedCrossRefGoogle Scholar
  18. Kerker, M., 1968, Light Scattering, The interface symposium, Indust.Eng. Chem., 60 (No. 10):31.Google Scholar
  19. Kirby, C., Clarke, J., and Gregoriadis, G., 1980, Effect of cholesterol content of small unilamellar liposomes on their stability in vitro and in vivo, Biochem. J., 186:591.PubMedGoogle Scholar
  20. Kramp, W., Pieroni, G., Pinckard, R. N., and Hanahan, D. J., 1984, Observations on the critical micellar concentration of l-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine and a series of its homologs and analogs, Chem.Phys.Lipids, 35:49.PubMedCrossRefGoogle Scholar
  21. Kumar, R., King, R. J., Mortin, H. M., and Hanahan, D. J., 1987, Metabolism of platelet activating factor (alkylacetylphosphocholine) by type-II epithelial cells and fibroblasts from rat lungs, Biochim.Biophys. Acta, 917:33.PubMedGoogle Scholar
  22. Lee, T. S., and Snyder, F., 1986, Function, metabolism and regulation of platelet activating factor and related ether lipids, in: “Phospholipids and cellular regulation,” J. F. Kuo, ed., Vol. II, CRC Press Inc, Bold Raton, FLorida.Google Scholar
  23. Levi, R., 1988, Models, mediators, mechanism and clinical considerations, in: “First Capri Conference on Clinical Immunology,” M. Condorelli et al, eds., B. C. Decker Inc., Toronto, in press.Google Scholar
  24. Ludwig, D. C., Hoppens, C. L., McManus, L. M., Mott, G. G., and Pinckard, R. N., 1985, Modulation of platelet activating factor synthesis and release from human polymorphonuclear leucocytes: Role of extra-cellular albumin, Archiv.Biochem.Biophys., 241:337.CrossRefGoogle Scholar
  25. Mallet, A. I., and Cunningham, F. M., 1985, Structural identification of platelet activating factor is psoriatic scale, Biochem.Biophys Res.Commun., 126:192.PubMedCrossRefGoogle Scholar
  26. Pattnaik, N. M., Kezdy, F. J., and Scanu, A. M., 1976, Kinetic Study of the action of snake venom phospholipase A2 on human serum high density lipoprotein 3*, J.Biol.Chem., 251:1984.PubMedGoogle Scholar
  27. Pinckard, R. N., McManus, L. M., Halonen, M., and Hanahan, D. J., 1982a Biological activities of acetyl glyceryl ether phosphorylcholine in experimental animals and in man, in: “Role of Chemical Meidators in the pathophysiology of acute illness and injury,” R. McConn, ed., Raven Press, New York.Google Scholar
  28. Pinckard, R. N., McManus, L. M., and Hanahan, D. J., 1982b Chemistry and Biology of acetyl glyceryl ether phosphorylcholine (platelet-activating factor), in: “Advances in Inflammation Research, “G. Weissman, ed., Vol. 4, Raven Press, New York.Google Scholar
  29. Reers, M., Elbracht, R., Rüdel, H., and Spener, E., 1984, Rapid methods for the characterization of unilamellar phospholipid vesicels. Application to studies on fatty acid donor and acceptor properties of membranes and fatty acid binding proteins, Chem.Phys.Lipids, 36:15.CrossRefGoogle Scholar
  30. Rosam, A. C., Wallace, J. L., and Whittle, B. J. R., 1986, Potent ulcerogenic actions of platelet-activating factor on the stomach, Nature, 319:54.PubMedCrossRefGoogle Scholar
  31. Schenkman, S., De Araugjo, P. S., Sesso, A., Quina, F. H., and Chaimovich, H., 1981, A kinetic and structural study of two-step aggregation and fusion of neutral phospholipid vesicels promoted by serum albumin at low pH, Chem.Phys.Lipids, 28:165.PubMedCrossRefGoogle Scholar
  32. Schlondorff, D., and Neuwirth, P., 1986, Platelet activating factor and the kidney, Ann.J.Physiol., 251:F1.Google Scholar
  33. Skrika, E., and Vakirtzi-Lemonias, C., 1984, Studies on stability of alklyacetyl glycerophosphatidylcholine (AGEPC) containing liposomes, 16th FEBS Meeting, Abstracts, p. 193.Google Scholar
  34. Stimler, N. P., Gerald, C., and O’Flaherty, J. I., 1983, Contraction of human lung tissue by platelet-activating actor, in: “Platelet activating factor and structurally related ether lipids,” J. Benveniste and B. Arnoux, eds., Inserum Symposium No 23, Elsevier Science Publishers.Google Scholar
  35. Switzer, S., and Eder, H. A., 1965, Transport of lysolecithin by albumin in human and rat plasma, J.Lipid Res., 6:506.PubMedGoogle Scholar
  36. Tanford, C., Buzell, J. G., Rands, D. G., and Swanson, S. A., 1955, The reversible expansion of bovine serum albumin in acid solutions, J.Am.Chem.Soc, 77:6421.CrossRefGoogle Scholar
  37. Tuffin, D. P., Davey, P., Dyer, R. L., Lunt, D. O., and Wade, P. J., 1985, Specific binding of 2H-1-o-octadecyl-PAF-acether to washed human platelets, Adv.Exp.Med.Biol., 192:83.PubMedGoogle Scholar
  38. Vakirtzi-Lemonias, C., 1984a, Acetyl glyceryl ether containing liposomes, in: “Liposome Technology,” G. Gregoriadis, ed., Vol.11, Chapter 6, CRC Press, Boca Raton, Florida.Google Scholar
  39. Vakirtzi-Lemonias, C., 1984b, Hydrolysis of I-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AGEPC) by mouse serum, Biochem.Soc.Trans., 19:689.Google Scholar
  40. Vakirtzi-Lemonias, C., and Gregoriadis, G., 1978, Uptake of Liposome-entrapped agents by the trypanosome Crithidia fasciculata, Biochem.Soc.Trans., 6:1241.PubMedGoogle Scholar
  41. Van Echteld, C. J. A., De Kruijff, B., Mandersloot, J. G., and De Gier, J., 1981, Effects of lysophosphatidylcholines on phosphatidylcholine and phosphatidylcholine/cholesterol liposome systems as revealed by 32P-NMR, electron microscopy and permeability studies, Biochim. Biophys.Acta, 649:211.PubMedCrossRefGoogle Scholar
  42. Vargaftig, B. B., Chignard, M., Benveniste, J., Lefort, J., and Wal, F., 1981, Background and present status of research on platelet-activating factor (PAF-acether), Annuals N.Y.Acad.Sci., 370:119.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • E. Skrika
    • 1
  • C. Vakirtzi-Lemonias
    • 1
  1. 1.Biology DivisionNuclear Research Center “Democritos”Aghia Paraskevi Attikis, AthensGreece

Personalised recommendations